Ultromics Raises $33M in Series B Funding to Help Transform Cardiac Disease Treatment
OXFORD, England, Aug. 16, 2021 /PRNewswire/ -- Ultromics, a leader in AI enabled cardiovascular imaging solutions, announced today that it has raised $33 million in a Series B funding round. The round was led by the Blue Venture Fund with participation from Optum Ventures, GV, and existing investor Oxford Sciences Innovation.
- Cardiovascular disease is the leading cause of mortality in the world, with an estimated 17 million deaths each year.
- Ultromics will use the new funding to help accelerate the use of AI-enabled echocardiograms to help improve patient care, and bring improved diagnostic quality and resource savings to hospitals.
- "Echocardiograms uploaded to the cloud and analyzed by artificial intelligence are set to revolutionize cardiac disease treatment pathways by helping more people understand their risk of heart disease earlier and with greater accuracy," said Dr. Ross Upton, CEO and co-founder of Ultromics.
- Oxford Sciences Innovation, an organization that helps scientific breakthroughs become world-changing businesses, helped get Ultromics' business off the ground, and doubled down on its support of Ultromics during the Series B funding round.